Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy

Ünal, Mustafa; Yücel, İclal; Akar, Yusuf

doi:10.1016/j.jcrs.2006.04.014

Cited by 13 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Barnes et al 2 reported a 2% rate among 47 patients treated with either acetazolamide or apracloni-dine. Unal et al 11 examined 115 patients and reported a stable IOP following apraclonidine and capsulotomy (from 16.1 to 15 mm Hg) and a relatively high rate of IOP spikes > 5 mm Hg seen in 8.6% (5/58) of their patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel

Achiron

2017

Journal of Current Glaucoma Practice

View full text Add to dashboard Cite

Aim The current treatment for posterior capsular opacification (PCO), neodymium-doped yttrium aluminum garnet (Nd:YAG) laser capsulotomy, may lead to increased intraocular pressure (IOP). Our aim was to survey routines in the management of IOP spikes and to identify the rate of IOP spikes following prophylactic apraclonidine treatment.Materials and methods A survey questionnaire among ophthalmologists and a retrospective registry review was used. Patients were administered apraclonidine 0.5% prior to capsulotomy. The IOP was measured before and 1 hour postprocedure.Results A total of 71% of responders (n = 45) routinely prescribe topical IOP-lowering medication and 82% routinely measure IOP before or after capsulotomy. The registry analysis included 87 eyes of 75 patients. Mean IOP decreased by 0.9 ± 3.3 mm Hg (p = 0.01, range: -6 to 10) following capsulotomy. No patient reached IOP values above 21 mm Hg following the procedure, with 3.4 and 1.1% of patients demonstrating an IOP elevation of more than 3 and 5 mm Hg respectively. No association was found between number of laser shots, mean laser power, or comorbid conditions, such as diabetes, hypertension, or glaucoma status with posttreatment IOP.Conclusion Most ophthalmologists surveyed routinely prescribe prophylactic IOP-lowering medication and measure IOP before or after capsulotomy. Mean IOP remained clinically stable following capsulotomy with prophylactic apraclonidine instillation, and no patient reached IOP values above 21 mm Hg. Differences in laser delivery or comorbid conditions were not associated with posttreatment IOP. Considering that no patient demonstrated a clinically significant IOP spike following prophylactic apraclonidine instillation, perhaps routine measurement of IOP following primary Nd:YAG laser may be reserved for high-risk patients only.Clinical significance In this work, we showed the prophylactic effect of apraclonidine 0.5% and suggest that measuring IOP after the procedure is necessary only in certain high-risk cases, possibly helping to reduce workload and patient waiting time and improving quality of service.How to cite this article Achiron A. Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel. J Curr Glaucoma Pract 2017;11(2):63-66.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 8 13 Reported rates of IOP spikes above 5 mm Hg following prophylactic apraclonidine 0.5% and capsulotomy vary between 2 and 8.5%. 2 5 11 12 …”

Section: Introductionmentioning

confidence: 99%

Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel

Achiron

2017

Journal of Current Glaucoma Practice

View full text Add to dashboard Cite

show abstract

“…Em concordância com a literatura (7,(16)(17)24) , constatou-se que houve um aumento significante da PIO nas primeiras duas horas e após esse período, a PIO retornou a valores iniciais. Após 2 horas, é raro haver picos hipertensivos após capsulotomia.…”

Section: Discussionunclassified

“…Estudos recentes apontam que o material e desenho das lentes intra-oculares de polimetilmetacrilato (PMMA) induzem mais à opacificação que as lentes de acrílico hidrófobo e lentes implantadas no sulco induzem a uma hipertensão maior que se fossem implantadas no saco capsular (12) . O controle da PIO tem sido feito por alguns agentes hipotensores oculares como bloqueadores adrenérgicos: maleato de timolol (3) e levobunolol (14) , parassimpáticomimético: pilocarpina (15) , inibidores da anidrase carbônica: acetazolamida sistêmica (16) e dorzolamida tópico (17)(18) , derivado da prostaglandina: latanoprosta (19) , agonistas adrenérgicos seletivos: apraclonidina (20) , brimonidina (21)(22)(23) e brinzolamida (24) . As possíveis vantagens e desvantagens dos diversos hipotensores disponíveis ainda não foram pesquisadas em uma única série.…”

Section: Resumo Introduçãounclassified

Eficácia de hipotensores oculares tópicos após capsulotomia posterior

Minello¹,

Prata²,

Mello³

2008

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…Teresa, Nancy and Unal in their study, showed that the use of brimonidine 0.15% before surgery is comparable to the efficacy and safeness of apraclonidine 0.5% and 0.1% in preventing IOP elevation after laser anterior segment capsulotomy. 5,6,16 Seong et al in a study identified the positive influence of brimonidine 0.2% as an eye drop in preventing IOP elevation after YAG laser capsulotomy. 7 Yeom and et al in a study used two different concentrations of brimonidine (0.2% and 0.15%) and showed their high effectiveness in preventing IOP rise after YAG laser capsulotomy and also they suggest that both drugs had a similar impact on preventing IOP increase.…”

Section: Xalatan Brimonidinementioning

confidence: 99%

Compare Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) in preventing intraocular pressure after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Ardabil city

Ojaghi

Masoumi

Eskandar-Sani

2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The transient increase of intraocular pressure (IOP) following neodymium YAG laser capsulotomy can occur in a significant number of patients, which requires prophylactic treatment with IOP reducing drugs, and in some patients, postoperative IOP monitoring. This study was performed to compare the efficacy of brimonidine 0.2% versus latanoprost0.005% (Xalatan) in preventing the IOP elevation after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Alavi Hospital.Methods: This study was a randomized, double-blind clinical trial that included 100 patients who had developed posterior capsule opacification (PCO) as a result of previous cataract surgery and were candidate for undergoing YAG laser posterior capsulotomy. The patients were randomly divided into two groups of 50 patients. One group received brimonidine 0.2% one hour before surgery, and the other group received Xalatan 0.005% in the night before laser surgery. In both groups the patients' IOP was measured in baseline, 1, 2, 3, 24 hours, 3 days and one week after surgery. The gathered data were analyzed using statistical methods in SPSS.16.Results: The mean IOP, 1, 2, 3, and 24 hours, 3 days, and one week after surgery didn't show any significant difference between two groups. IOP one hour before surgery changed significantly compared to one hour after surgery and a statistically significant relationship was found between the two groups, though at other times of measurement, the differences were not significant.Conclusions: Results showed that using Brimonidine 0.2% or Latanoprost 0.005% as prophylactic before YAG laser posterior capsulotomy could be effective in preventing IOP after treatment.

show abstract

Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy

Abstract: Brinzolamide 1% and apraclonidine 0.5% given prophylactically before Nd:YAG laser capsulotomy were effective in preventing IOP spikes after treatment.

Cited by 13 publications

References 24 publications

Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel

Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel

Eficácia de hipotensores oculares tópicos após capsulotomia posterior

Compare Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) in preventing intraocular pressure after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Ardabil city

Contact Info

Product

Resources

About